Tissue Regenix Group plc

TRX.L · LSE
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-£392-£1,713-£2,188-£3,484
Dep. & Amort.£1,046£977£921£793
Deferred Tax£0£0-£2,592-£2,037
Stock-Based Comp.£363£342£249£110
Change in WC-£3,588-£239-£500-£340
Other Non-Cash£936£1,673£2,815£1,983
Operating Cash Flow-£1,635£1,040-£1,409-£2,445
Investing Activities
PP&E Inv.-£3,299-£413-£885-£1,488
Net Acquisitions£0£0£0£0
Inv. Purchases£0£0£0£0
Inv. Sales/Matur.£0£0£0£0
Other Inv. Act.-£759-£424-£197-£556
Investing Cash Flow-£4,058-£837-£1,082-£2,044
Financing Activities
Debt Repay.£4,253-£238£1,387£438
Stock Issued£104£74£9£0
Stock Repurch.£0£0£0£0
Dividends Paid£0£0£0£0
Other Fin. Act.-£1,078-£1,348-£486-£630
Financing Cash Flow£3,279-£1,512£910-£192
Forex Effect-£21£10-£294-£48
Net Chg. in Cash-£2,435-£1,299-£1,760-£5,259
Supplemental Information
Beg. Cash£4,650£5,949£5,692£9,550
End Cash£2,215£4,650£4,946£5,692
Free Cash Flow-£5,704£177-£2,294-£3,934
Tissue Regenix Group plc (TRX.L) Financial Statements & Key Stats | AlphaPilot